Rapid skeletal turnover in a radiographic mimic of osteopetrosis

Journal of Bone and Mineral Research

Volumn 29, Issue 12, 2014, Pages 2601-2609

  Whyte, Michael P ^a,b   Madson, Katherine L ^a   Mumm, Steven ^a,b   McAlister, William H ^c   Novack, Deborah V ^b   Blair, Jo C ^d   Helliwell, Timothy R ^e   Stolina, Marina ^f   Abernethy, Laurence J ^d   Shaw, Nicholas J ^g  

^a SHRINERS HOSPITAL FOR CHILDREN   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f AMGEN INC   (United States)

^g BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Biomarker profiling; Giant cell granuloma; Osteosclerosis; Sclerostin

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE; CORTICOTROPIN; CREATININE; DEOXYPYRIDINOLINE; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PYRIDINOLINE; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1; VITAMIN D; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

AGE; ALBERS SCHOENBERG DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTERIOR CRANIAL FOSSA; ANTICOAGULANT THERAPY; ARTICLE; BONE DENSITY; BONE PAIN; BONE RADIOGRAPHY; BONE REMODELING; BONE SCINTISCANNING; BONE TURNOVER; BRAIN INFARCTION; CALCIUM INTAKE; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CELL INCLUSION; CHILD; CLINICAL FEATURE; CORTICAL THICKNESS (BONE); CORTICOTROPIN BLOOD LEVEL; DECIDUOUS TOOTH; DIETARY REFERENCE INTAKE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GIANT CELL GRANULOMA; HEADACHE; HIP; HISTOPATHOLOGY; HUMAN; HYPERPHOSPHATASEMIA; HYPERTELORISM; ILIAC CREST; LEG PAIN; LETHARGY; LUMBAR SPINE; MALE; MANDIBLE; MAXILLA; MUSCLE TONE; NECK; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OSTEOCLAST; OSTEOID; OSTEOSCLEROSIS; PALLOR; PARALYSIS; PROTHROMBIN TIME; PRURITUS; SCHOOL CHILD; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKULL BASE; SPINDLE CELL; STROMA; THORAX RADIOGRAPHY; TRABECULAR BONE; VITAMIN SUPPLEMENTATION; VOMITING; BLOOD; OSTEOPOROSIS; PATHOPHYSIOLOGY; RADIOGRAPHY; SKELETON; SYNDROME;

BONE REMODELING; CHILD; DIPHOSPHONATES; HUMANS; MALE; OSTEOPOROSIS; OSTEOSCLEROSIS; SKELETON; SYNDROME;

EID: 84918502463     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2289     Document Type: Article

References (57)

1. Whyte MP. Searching for gene defects that cause high bone mass. Am J Hum Genet. 1997;60: 1309-11.
2. Perdu B, Van Hul W. Sclerosing bone disorders. In: Thakker RV, Whyte MP, Eisman JA, Igarashi T, editors. Genetics of bone biology and skeletal disease. San Diego, CA: Academic Press; 2013. p.361-74.
3. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone mass trait. Am J Hum Genet. 2002;70: 11-9.
4. Van Wesenbeeck L, Cleiren E, Gram J, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet. 2003;72: 763-71.
5. Leupin O, Piters E, Halleux G, et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286: 19489-500.
6. Kozlowski K, Beighton P. Gamut index of skeletal dysplasias. An aid to radiodiagnosis. 2nd ed. London: Springer-Verlag; 1995.
7. Whyte MP. Osteopetrosis. In: Royce PM, Steinmann B, editors. Connective tissue and its heritable disorders: Molecular, genetic, and medical aspects. 2nd ed. New York: Wiley-Liss; 2002. p.789-807.
8. Whyte MP, Kempa LG, McAlister WH, Zhang F, Mumm S, Wenkert D. Elevated serum lactate dehydrogenase isoenzymes and aspartate transaminase distinguish Albers-Schönberg osteopetrosis (chloride channel 7 deficiency) among the sclerosing bone disorders. J Bone Miner Res. 2010;25: 2515-26.
9. Whyte MP, Chines A, Silva DP, Landt Y, Ladenson JH. Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders. J Bone Miner Res. 1996;11: 1438-43.
10. Whyte MP, Wenkert D, Dwyer DC, Lacey DL, Stolina M. Systemic biomarker profiling of metabolic and dysplastic skeletal diseases using multiplex serum protein analyses [Abstract]. J Bone Miner Res. 2010;25(Suppl 1): S137.
11. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39(2): 91-7.
12. Häusler KD, Horwood NJ, Chuman Y, et al. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res. 2004;19(11): 1873-81.
13. Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet. 2007;39: 960-2.
14. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002;347: 175-84.
15. Whyte MP, Wenkert D, McAlister WH, et al. Dysosteosclerosis presents as an "osteoclast-poor" form of osteopetrosis: Comprehensive investigation of a 3-year-old girl and literature review. J Bone Miner Res. 2010;25: 2527-39.
16. Whyte MP, Totty WG, Novack DV, Zhang X, Wenkert D, Mumm S. Camurati-Engelmann disease: Unique variant featuring a novel mutation in TGFb1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand. J Bone Miner Res. 2011;26: 920-33.
17. Janssens K, Gershoni-Baruch R, Guanabens N, et al. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet. 2000;26: 273-5.
18. Kinoshita A, Saito T, Tomita H, et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet. 2000; 26: 19-20.
19. Guerrini MM, Sobacchi C, Cassani B, et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet. 2008;83: 64-76.
20. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70: 1582-8.
21. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346: 1513-21.
22. Whyte MP, Reinus WH, Mumm S. High-bone-mass disease and LRP5 [Letter]. N Engl J Med. 2004;350(20): 2096-9.
23. Sobacchi C, Schulz A, Coxon FR, Villa A, Helfrich MH. Osteopetrosis: Genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9: 522-38.
24. Whyte MP, McAlister WH, Novack DV, Clements KL, Schoenecker PL, Wenkert D. Bisphosphonate-induced osteopetrosis: Novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res. 2008;23: 1698-707.
25. Kalkwarf HJ, Zemel BS, Gilsanz V, Lappe JM, Horlick M, Oberfield S, Mahboubi S, Fan B, Frederick MM, Winer K, Shepherd JA. The bone mineral density in childhood study: Bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab. 2007;92(6): 2087-2099.
26. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003;349: 455-61.
27. Whyte MP. Sclerosing bone disorders. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. Hoboken: Wiley; 2013. p.769-85.
28. Ihde LL, Forrester DM, Gottsegen CF, et al. Sclerosing bone dysplasias: Review and differentiation from other causes of osteosclerosis. Radiographics. 2011;31: 1865-82.
29. Gregson CL, Hardcastle SA, Cooper C, Tobias JH. Friend or foe: High bone mineral density on routine bone density scanning, a review of causes and management. Rheumatology. 2013;52: 968-85.
30. Aggarwal S. Skeletal dysplasias with increased bone density: Evolution of molecular pathogenesis in the last century. Gene. 2013;528: 41-5.
31. Thakker RV, Whyte MP, Eisman JA, Igarashi T. editors. Genetics of bone biology and skeletal disease. San Diego, CA: Academic Press; 2013.
32. Reeder MM. Reeder and Felson's gamuts in bone, joint and spine radiology: Comprehensive lists of Roentgen differential diagnosis. New York: Springer-Verlag; 1993.501 p.
33. Faden MA, Krakow D, Ezgu F, Rimoin DL, Lachman RS. The Erlenmeyer flask bone deformity in the skeletal dysplasias. Am J Med Genet. 2009;149A: 1334-45.
34. Sule G, Campeau PM, Zhang VW, et al. Next-generation sequencing for disorders of low and high bone mineral density. Osteoporos Int. 2013;24: 2253-9.
35. Whyte MP. Mendelian disorders of RANKL/OPG/RANK signaling. Thakker RV, Whyte MP, Eisman JA, Igarashi T, editors. Genetics of bone biology and skeletal disease. San Diego, CA: Academic Press; 2013. p.309-24.
36. Jaffe HI. Giant cell reparative granuloma, traumatic bone cyst, and fibrous (fibro-osseous) dysplasia of the jaw bones. Oral Surg. 1953;6: 159-75.
37. Nogueria RLM, Faria MHG, Osterne RLV, Cavalcante RB, Ribeiro RA, Rabenhorst SHB. Glucocorticoid and calcitonin receptor expression in central giant cell lesions: Implications for therapy. Int J Oral Maxillofac Surg. 2012;41: 994-1000.
38. Maron E, Kachko L, Brennan PA, Bodner L. Cytogenetics of central giant cell granuloma of the mandible. J Oral Maxillofac Surg. 2013;71: 1541-4.
39. deLange J, van den Akker HP, van den Berg H. Central giant cell granuloma of the jaw: A review of the literature with emphasis on therapy options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104: 603-15.
40. Borges BBP, Fornazieri MA, Correia de Araujo Bezerra AP, Martins LAL, de Rezende Pinna F, Voegels RL. Giant cell lesions in the craniofacial region: A diagnostic and therapeutic challenge. Int Forum Allergy Rhinol. 2012;2: 501-6.
41. Gianfrancesco F, Rendina D, Merlotti D, et al. Giant cell tumor occurring in familial Paget's disease of bone: Report of clinical characteristics and linkage analysis of a large pedigree. J Bone Miner Res. 2013;28: 341-50.
42. Upchurch KS, Simon LS, Schiller AL, Rosenthal DI, Campion EW, Krane SM. Giant cell reparative granuloma of Paget's disease of bone: A unique clinical entity. Ann Intern Med. 1983;98: 35-40.
43. Ziambaras K, Totty WA, Teitelbaum SL, Dierkes M, Whyte MP. Extraskeletal osteoclastomas responsive to dexamethasone treatment in Paget bone disease. J Clin Endocrinol Metab. 1997;82: 3826-34.
44. Kim GS, Kim SH, Cho JK, et al. Paget bone disease involving young adults in a three-generation Korean kindred. Medicine (Baltimore). 1997;76: 157-69.
45. Robinson D, Einhorn TA. Giant cell tumor of bone: A unique paradigm of stromal-hematopoietic cellular interactions. J Cell Biochem. 1994;55: 300-3.
46. Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol. 2002;117: 210-6.
47. van Bezooijen RL, Roelen BAJ, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199: 805-14.
48. Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Jumta SM. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int. 2004;75: 71-7.
49. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013 Aug;14(9): 901-8.
50. Karras NA, Polgreen LE, Ogilvie C, Manivel JC, Skubitz KM, Lipsitz E. Denosumab treatment of metastatic giant-cell tumor of bone in a 10- year-old girl. J Clin Oncol. 2013;31(12): E200-2.
51. Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone-A review and future management considerations. Curr Oncol. 2013;20: 442-7.
52. Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E. First use of the RANKL antibody denosumab in osteogenesis imperfecta Type VI. J Musculoskelet Neuronal Interact. 2012;12: 183-8.
53. Boyce AM, Chong WH, Yao J, et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res. 2012;27: 1462-70.
54. Grasemann C, Schündeln M, Hövel M, et al. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease. J Clin Endocrinol Metab. 2013;98: 3121-6.
55. Shroff R, Beringer O, Rao K, Hofbauer LC, Schulz A. Denosumab for post-transplantation hypercalcemia in osteopetrosis [Letter to Editor]. N Engl J Med. 2012;367(18): 1766-7.
56. Malmquist M, Schow SR. Treatment of central giant cell granuloma with denosumab therapy in two patients. J Oral Maxillofac Surg. 2013;71(9) (Suppl 1): E75.
57. Polyzos SA, Anastasilakis AD, Litsas I, et al. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. J Bone Miner Metab. 2010;28: 706-12.